Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577722 | 0.90 | SMN1; SMN2 (0.55) | CHRM3ALDH1A1SMN1; SMN2 | |
| SCHEMBL5577857 | 0.86 | CHRM3 (0.52) | LMNACHRM3SMN1; SMN2SIGMAR1KMT2A | |
| SCHEMBL5577666 | 0.86 | CHRM3 (0.52) | LMNACHRM3SMN1; SMN2KMT2AMAPT | |
| SCHEMBL5577442 | 0.85 | CHRM3 (0.58) | CHRM3SMN1; SMN2 | |
| SCHEMBL5577493 | 0.85 | SMN1; SMN2 (0.58) | LMNACHRM3ALDH1A1SMN1; SMN2 | |
| SCHEMBL5577883 | 0.85 | CHRM3 (0.55) | LMNACHRM3SMN1; SMN2KMT2AMAPT | |
| SCHEMBL5577458 | 0.84 | CHRM3 (0.61) | CHRM3ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5577397 | 0.83 | ALDH1A1 (0.55) | CHRM3GAAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL5577893 | 0.83 | SMN1; SMN2 (0.51) | CHRM3ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL5577909 | 0.82 | SMN1; SMN2 (0.52) | LMNACHRM3ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | LMNA 4819/4885CHRM3 2099/4885GAA 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.